Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology and Autoinflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ALPK1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ALPK1 Recombinant Protein (Kinase Domain). High purity (>95%), Endotoxin <1EU/ug. ATP-binding site intact. Sequence Verified. | View ALPK1 Products |
| Gene Delivery | ALPK1 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. | View ALPK1 Products |
| Benchmark Ab | Anti-ALPK1 Antibody (Recombinant Rabbit mAb). Positive control for target engagement, Western/IF. Sequence Verified. | View ALPK1 Products |
| Validator | ALPK1 siRNA Set. Validated knockdown efficiency for specificity controls. | View ALPK1 Products |
| Substrate Partner | TIFA (TRAF-interacting protein). Recombinant full-length for phosphorylation assays. Direct downstream substrate essential for NF-κB pathway activation. | View TIFA Products |
| Related Target A | STING1. Parallel innate immune sensing pathway for synergistic therapeutic strategies. | View STING1 Products |
| Paralog Control | ALPK2 Kinase Domain. For selectivity screening vs close homolog. High Purity (>95%). | View ALPK2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Activity Validation | Optimized expression constructs to preserve the active kinase conformation. High Purity (>95%). |
| Substrate-specific Phosphorylation (TIFA Thr9) | Active ALPK1 Kinase Domain with validated autophosphorylation capacity; matched TIFA substrate available for direct activity readout. |
| Paralog Selectivity (vs ALPK2) | ALPK1 and ALPK2 ortholog proteins with <90% homology mapping for side-by-side screening. |
| ROSAH Mutation Modeling | Custom Mutant Protein Service: Gly1022Ser, Ala1017Pro variants available upon request. |
| Cellular / Cytosolic Target Engagement | Lentivirus premade particles for stable overexpression in HEK293/THP-1 cells. Endotoxin <10 EU/mL. Reporter cell lines available for NF-κB activation. |
| Lack of Controls | Clinical Benchmark Antibodies included for reliable assay normalization. |
| False Positives | Validated siRNA included for absolute specificity checks in cell-based assays. |
Live ALPK1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Mechanism Research
- ➤ ROSAH & Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The therapeutic focus on ALPK1 is bifurcating: targeting gain-of-function mutations in ROSAH syndrome (autoinflammatory) and exploring its role as an innate immune agonist in oncology immunomodulation. On the oncology front, first-generation ALPK1 small molecule agonists are navigating early clinical trials, with a shift toward targeted agonist conjugates (such as ISACs or peptide-drug conjugates) to localize immune activation within the tumor microenvironment, minimizing systemic cytokine release. In parallel, inhibitors of ALPK1 are being advanced by Apeiron/Alphageneron for ROSAH syndrome and related autoinflammatory conditions, emphasizing selective allosteric inhibitors to avoid off-target kinase effects. As an intracellular pattern recognition receptor, ALPK1 activates robust innate immunity via TIFA and NF-κB, making it a compelling yet challenging target for both activation and inhibition strategies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonists | Boehringer Ingelheim | Solid Tumors | Biochemical Kinase Assays (Need high-purity active ALPK1 proteins) |
| Small Molecule Inhibitors | Apeiron Biologics, Alphageneron | ROSAH Syndrome, Autoinflammatory Diseases | ATP-competition & Allosteric Binding (Need active Kinase domain with intact ATP pocket) |
| Targeted Conjugates (ISACs, Peptide-drug) | Bicycle Therapeutics | Advanced Solid Tumors | Cell-based Activation Profiling (Need stable reporter cell line tools) |
| Chemical Probe/Tool | SGC (Structural Genomics Consortium) | Mechanism Research | High-resolution Crystal Structure Support (Need homogeneous protein) |
| Gene Therapy / RNAi | Academic / Emerging Biotech | Inflammatory Diseases / Gain-of-function Mutations | Knockdown Verification (Need verified siRNA and specific antibodies) |